Biosimilars

COVID-19

Cataract Surgery

Cataract

Cataract Therapeutics

NeuroOp Guru

Clinical Diagnosis

Cornea

Dry Eye Awareness

Dry Eye

Gene Therapy

Geographic Atrophy

IOL Advances

Imaging

Glaucoma Awareness

Glaucoma Insights

Therapeutic Glaucoma

Interventional Glaucoma

Ocular Allergy

Ocular Surface Disease

Optic Relief

Optometry

Pediatrics

Pharmacy

Indispensable

Practice Management

Presbyopia

Ptosis

Refractive Surgery

Refractive

Retina

Surgery

Technology

Therapeutics

Understanding Antibiotic Resistance

Workplace

News

All News

Contributors

Money Matters

Media

All Videos

Expert Interviews

Medical World News

Podcasts

Case Based Roundtable Series

Case of the Quarter

EyeView

Grand Rounds

Insights

Rapid Readout

Viewpoints

What’s Your WhEYE?

Conferences

Conference Coverage

Conference Listing

Events

Publications

Digital Edition

Europe Ophthalmology Times

Modern Retina

Supplements and Featured Publications

Partners

Subscribe

Resources

Job Board

Articles

Intraoperative floppy iris syndrome is associated with an increased rate of severe intraoperative complications and greater visual morbidity during cataract surgery

Floppy iris syndrome risk: Study finds women more susceptible, key drugs identified

CEO Stephen McLeod, MD, outlines the American Academy of Ophthalmology's commitment to advocating for evidence-based, sustainable, and equitable reforms that prioritize public health and access to quality care.

Staying the course in shifting winds

The bio-interventional platform is for uveoscleral outflow enhancement in open-angle glaucoma patients undergoing combined cataract surgery.

Iantrek announces positive 2-year results from clinical study of its bio-interventional platform for uveoscleral outflow enhancement

A retrospective study showed that the gender of the ophthalmologist influenced the amount of communication with the patient, and that the pandemic had an impact. 

How COVID-19 shifted ophthalmologist-patient communication

Ophthalmology Times - ophthalmology news, articles, and events in a timely and accurate manner for members of the ophthalmic community.

About

Advertise

Privacy

Editorial Info

Editorial Board

Terms and Conditions

Contact Us

Do Not Sell My Personal Information

Ophthalmology Times - Ophthalmology news, articles, and events

Facebook

Instagram

LinkedIn

Spotlight

Clinical

Glaucoma

View

Vancouver, British Columbia-An $855 million deal will unite verteporfin (Visudyne) developer QLT Inc. and Atrix Laboratories Inc. to build QLT's business and accelerate strategic initiatives.

Verteporfin-maker QLT to merge with Atrix